Bolt Biotherapeutics (BOLT) Competitors $0.57 0.00 (-0.79%) (As of 09:33 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestTrends BOLT vs. AGEN, FBIO, SABS, CRIS, MTEM, AMGN, VRTX, GILD, REGN, and ALNYShould you be buying Bolt Biotherapeutics stock or one of its competitors? The main competitors of Bolt Biotherapeutics include Agenus (AGEN), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Curis (CRIS), Molecular Templates (MTEM), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Alnylam Pharmaceuticals (ALNY). These companies are all part of the "biotechnology" industry. Bolt Biotherapeutics vs. Agenus Fortress Biotech SAB Biotherapeutics Curis Molecular Templates Amgen Vertex Pharmaceuticals Gilead Sciences Regeneron Pharmaceuticals Alnylam Pharmaceuticals Agenus (NASDAQ:AGEN) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings, community ranking and dividends. Which has stronger valuation & earnings, AGEN or BOLT? Bolt Biotherapeutics has lower revenue, but higher earnings than Agenus. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgenus$156.31M0.39-$245.76M-$11.24-0.23Bolt Biotherapeutics$7.88M2.75-$69.20M-$1.71-0.33 Is AGEN or BOLT more profitable? Agenus has a net margin of -145.89% compared to Bolt Biotherapeutics' net margin of -665.56%. Agenus' return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Agenus-145.89% N/A -85.68% Bolt Biotherapeutics -665.56%-69.46%-48.55% Do analysts recommend AGEN or BOLT? Agenus presently has a consensus price target of $10.00, suggesting a potential upside of 281.68%. Bolt Biotherapeutics has a consensus price target of $3.50, suggesting a potential upside of 518.92%. Given Bolt Biotherapeutics' higher probable upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Agenus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agenus 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17Bolt Biotherapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders & institutionals have more ownership in AGEN or BOLT? 61.5% of Agenus shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 4.6% of Agenus shares are held by company insiders. Comparatively, 30.9% of Bolt Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, AGEN or BOLT? Agenus has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Does the MarketBeat Community prefer AGEN or BOLT? Agenus received 387 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. Likewise, 69.49% of users gave Agenus an outperform vote while only 64.52% of users gave Bolt Biotherapeutics an outperform vote. CompanyUnderperformOutperformAgenusOutperform Votes46769.49% Underperform Votes20530.51% Bolt BiotherapeuticsOutperform Votes8064.52% Underperform Votes4435.48% Does the media prefer AGEN or BOLT? In the previous week, Agenus had 5 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 12 mentions for Agenus and 7 mentions for Bolt Biotherapeutics. Agenus' average media sentiment score of -0.12 beat Bolt Biotherapeutics' score of -0.72 indicating that Agenus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bolt Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative SummaryAgenus beats Bolt Biotherapeutics on 11 of the 18 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLT vs. The Competition Export to ExcelMetricBolt BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.64M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-0.334.8587.8613.46Price / Sales2.75374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book0.3010.216.946.30Net Income-$69.20M$153.61M$119.12M$225.93M7 Day Performance-9.14%-2.00%-1.84%-1.32%1 Month Performance-11.31%-7.47%-3.65%0.60%1 Year Performance-34.62%31.80%31.64%26.23% Bolt Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLTBolt Biotherapeutics3.3839 of 5 stars$0.57-0.8%$3.50+518.9%-37.7%$21.64M$7.88M-0.33100AGENAgenus3.8851 of 5 stars$2.62-1.9%$10.00+281.7%-82.0%$61.47M$156.31M0.00389Analyst RevisionFBIOFortress Biotech3.0653 of 5 stars$1.58+0.3%$13.67+767.7%-43.9%$43.47M$84.51M0.00186Analyst ForecastAnalyst RevisionSABSSAB Biotherapeutics3.5154 of 5 stars$3.06-5.6%$12.40+305.2%+267.0%$28.24M$2.24M0.00140CRISCuris2.0186 of 5 stars$3.70-2.4%$23.00+521.6%-56.3%$22.13M$10.02M-0.4749MTEMMolecular Templates2.2363 of 5 stars$0.39+1.5%N/A-92.0%$2.59M$57.31M0.0062Insider TradeAMGNAmgen4.9084 of 5 stars$285.11-1.0%$333.57+17.0%+8.5%$153.26B$28.19B36.8626,700Ex-DividendShort Interest ↓VRTXVertex Pharmaceuticals4.0527 of 5 stars$447.65-0.8%$499.12+11.5%+26.5%$115.28B$9.87B0.005,400Analyst DowngradeNews CoveragePositive NewsGILDGilead Sciences4.549 of 5 stars$88.29-0.4%$94.45+7.0%+16.6%$110.03B$27.12B984.7818,000Analyst UpgradePositive NewsREGNRegeneron Pharmaceuticals4.7877 of 5 stars$743.35-0.2%$1,099.55+47.9%-7.3%$81.69B$13.12B18.4013,450ALNYAlnylam Pharmaceuticals4.3981 of 5 stars$247.58-0.5%$298.09+20.4%+50.5%$31.93B$1.83B0.002,100Analyst Forecast Related Companies and Tools Related Companies Agenus Alternatives Fortress Biotech Alternatives SAB Biotherapeutics Alternatives Curis Alternatives Molecular Templates Alternatives Amgen Alternatives Vertex Pharmaceuticals Alternatives Gilead Sciences Alternatives Regeneron Pharmaceuticals Alternatives Alnylam Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BOLT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BOLT Stock Alerts